Clinical Trial

A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.
Protocol Amendment History 3 changes
critical Trial completed 2026-04-24
notable Primary completion pushed: 2026-03 -> 2026-04-10 2026-04-24
minor Completion pushed: 2026-03 -> 2026-04-10 2026-04-24
Trial Details
NCT Number NCT07137689
Lead Sponsor Eli Lilly and Company
Conditions Renal Insufficiency
Enrollment 32 participants
Start Date 2025-08-18
Primary Completion 2026-04-10 (estimated)
Study Completion 2026-04-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-23